Navigation Links
Shire Acquires US Rights to Resolor® (prucalopride)
Date:1/10/2012

other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


For further information please contact:

Investo
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Shire Provides Update on ProAmatine® (midodrine HCl)
2. National Pharmaceutical Council Welcomes Shire as Its Newest Member
3. Shire plc: Board Changes
4. Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
5. Shire plc : Second Quarter 2011 Results Date Notification - July 28, 2011
6. Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents
7. United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk
8. Shire Completes Acquisition of Advanced BioHealing, Inc.
9. European Authorities Approve New Manufacturing Facility for Shires REPLAGAL® (agalsidase alfa)
10. Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
11. Shire Recognized by ISPE Facility of the Year Awards Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
(Date:7/30/2015)... NJ (PRWEB) , ... July 30, 2015 , ... ... Jersey's State-designated entity on behalf of the New Jersey Department of Health, has ... Health Information Technology, an agency of the U.S. Department of Health and Human ...
(Date:7/30/2015)... ... July 30, 2015 , ... 1Heart Caregiver Services LLC is offering its ... Make Money in the Booming Homecare Business.” This will be held in its main ... , The event will be hosted by 1Heart’s very own Randy Clarito (Director of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After a ... Argus II retinal implant, more commonly known as the “bionic eye,” researchers have determined ... safe and viable tool for patients facing or already affected by complete vision loss ...
(Date:7/30/2015)... Santa Rosa, CA (PRWEB) , ... July 30, 2015 , ... At the presentation of ... topic of discussion was focused on research presented by the Journal of Arthroplasty ... normal tasks – like driving. , Results of the study confirm what Santa ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... for women to ensure their children have the nutrition required to grow into ... by offering discount cards for many prescription pre-natal vitamins. , Folic Acid , ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4
... Innovative technology such as electronic wristbands is developed to ... Human errors. Wristbands are developed which provides information about ... used in hospitals now to prescribe, dispense and administer ... bands contain electronic system which is similar to the ...
... the clinical trials involving lung cancer patients and it ... a frontline therapy for those with lung cancer. One ... regime in the elderly patients is the tolerability and ... tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity ...
... of Fair Trading is responsible for checking the profits ... to the NHS. They have to monitor that only ... should be reasonable. ,The Pharmaceutical Price Regulation ... legislates the agreement of the pricing and quality of ...
... out of deprivation from being in poverty and poor ... for heart disease is potentially denying// life saving preventive ... published ahead of print in the journal Heart. ... being allocated "primary preventive" treatment, is currently calculated using ...
... Mammography is used for early detection of breast cancer and ... year and self examination of the breasts for lumps every ... of cancer is necessary to start an early treatment which ... reported in the New England Journal of Medicine has shown ...
... called villi which increase the surface area of the intestine ... are covered in epithelial cells // which are constantly renewed ... top of the villi every day. ,Scientists found ... the bowel which, in healthy tissue, are immediately filled with ...
Cached Medicine News:Health News:Tarceva Found To Benefit Older Lung Cancer Patients 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Deprivation Can Cause Undetected Heart Problems 2Health News:Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts 2